Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX)

60 Hampshire St.
Cambridge, MA 02139 (Map)
Phone: 617-995-9800
Fax: 617-995-9801
http://www.idenix.com

Hoover's coverage by Kathryn Mackenzie

Overview

Idenix Pharmaceuticals is not suffering from an identity crisis -- it is clear in its focus on identifying treatments for viral diseases. The firm develops orally administered drugs to combat chronic hepatitis C (HCV). It has one marketed drug for hepatitis B (HBV), Telbivudine, sold under the brand names Tyzeka in the US and Sebivo internationally. It markets the product with Novartis, which also owns about 40% of Idenix. As part of the arrangement, Idenix receives royalties from Novartis for telbivudine sales. Idenix's other candidates are in various stages of clinical testing. Most are intended to be taken in combination with other therapeutic agents to improve efficacy and convenience.

Sample Overview

Key Numbers from Hoover's UK

Key financials for Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX)

Company Type Public (NASDAQ: IDIX)
Fiscal Year-End December
2010 Sales (mil.) £6.6
1-Year Sales Growth (19.0%)
2010 Net Income (mil.) (£39.8)
2010 Employees 109
1-Year Employee Growth (24.3%)
Get more Key Numbers
TIP: Understand how a company performs against its industry by reviewing Comparison Data. Column-to-column comparisons to the industry and the market are available with a Hoover's subscription.
TIP: Subscribers have access to detailed financial data (income statement, balance sheet, cash flow) for more than 500,000 public and private companies in the UK.

Key People from Hoover's UK

Key people and executives for Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX)

President, CEO, and Director Ronald C. (Ron) Renaud Jr.
(Subscribers see complete biographies -- view sample)
VP Corporate Communications Amy Sullivan
Senior Manager Corporate Communications Teresa (Teri) Dahlman
TIP: Use Build Executive List to target decision makers by industry, geography, sales, net income, and number of employees.

Top Competitors from Hoover's UK

Top competitors of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX)

There are 14 competitors for Idenix Pharmaceuticals; see more.
TIP: Analyze the Competitive Landscape to view a head-to-head comparison of a firm's profitability, operations, growth, and valuation versus that of its top three competitors.

Significant Developments

View company events at Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) such as IPOs, bankruptcies, or executive changes

Event Details
Top Executive Change Subscribers get full details --
view a sample
Top Executive Change
More Significant Developments

Industry Information from Hoover's UK

First Research Industry Profiles Extensive Industry Intelligence

Hoover's Industries

More Industry Information
TIP: Hoover's proprietary industry structure allows you to tell at-a-glance how diversified a company's operations are, and which line of business can be considered a company's primary industry.

Rankings from Hoover's UK

See how Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones

TIP: Hoover's subscribers have access to FT 500 and other rankings that make targeted list building easy.

Subscribers Get More!

Search Hoover's UK

View Hoover's UK Free Content

Buy A Report on Idenix Pharmaceuticals:

Sample UK Subscriber Content


Bizmology

No Christmas wrapping on toy safety reforms

by Linnea Kirgan, Jan. 2nd, 2008
Read more at Bizmology.com.


Companies That Exceed Expectations

Who's going above and beyond the status quo? Learn more about these groundbreaking companies!

Current Edition: Click Here



Small Business Expert

Presented by Comcast Business Class

Read More from the Current Edition: Performance Reviews

Click Here


Copyright © 2012, Hoover's, Inc., All Rights Reserved. Legal Terms | Privacy Policy